Can people swap their weight-loss shot for a daily pill and still keep the weight off?
Yes. In this phase 3b trial of 376 adults who had already lost weight on tirzepatide or semaglutide injections, switching to the daily oral pill orforglipron held onto most of that weight loss over a full year, while placebo did not. People who switched from the shot to the pill kept around three-quarters or more of their earlier weight loss.
Weight regain is one of the hardest problems in obesity care. Injectable GLP-1 drugs like tirzepatide and semaglutide work well, but people often regain weight when they stop. Many people also struggle with the shots themselves because of cost, needle fear, or travel. A pill version that could hold onto the weight loss would change how doctors manage obesity long term.
What the data show
The ATTAIN-MAINTAIN trial included 376 adults with obesity at 29 sites across the United States. Everyone had already lost weight on either tirzepatide (cohort 1) or semaglutide (cohort 2) during the earlier SURMOUNT-5 study. They were then randomly assigned to take orforglipron once daily or a placebo pill for 52 weeks.
In the tirzepatide group, people who switched to orforglipron held onto about 74.7% of their earlier weight loss at one year. People who switched to placebo kept only 49.2%. That is a 25.5 percentage point gap in favor of the pill. In the semaglutide group, the difference was even larger. The orforglipron group preserved about 79.3% of their weight loss, while the placebo group held onto just 37.6%, a gap of 41.7 percentage points. Both differences were highly statistically significant.
The benefits were not limited to weight. People who stayed on orforglipron also kept the improvements in waist size, blood pressure, cholesterol levels, and blood sugar markers that they had gained on the injectable drug. About three out of four participants finished the full year of treatment.
Dr. Kumar’s Take
I find this trial genuinely practical. The hard part of obesity care is not getting people to lose weight, it is helping them keep it off without staying on a weekly shot forever. An effective daily pill changes that conversation. It also removes real-world barriers like injection fear, cold storage during travel, and the higher cost of injectables in many parts of the world.
That said, this study compared the pill to placebo, not to staying on the original injection. So we still do not know how the pill stacks up against simply continuing tirzepatide or semaglutide. The trial also lasted only one year. Obesity is a lifelong condition, so we will need longer data before this becomes the default maintenance plan. For now, this is strong evidence that an oral GLP-1 can preserve most of the weight loss from a shot, and that is a real step forward.
How the trial was run
This was a double-blind, placebo-controlled phase 3b study, which is the strongest kind of evidence short of a head-to-head comparison with the original injectable drug. Participants did not know whether they were taking the active pill or placebo, and neither did their doctors during the trial. The orforglipron dose was 36 mg once daily, or the highest dose each person could tolerate. The trial population was mostly women, mostly white, with an average age in the late 40s and an average starting weight around 90 to 94 kg.
Safety, limits, and caveats
The most common side effects with orforglipron were gastrointestinal, things like nausea, diarrhea, or stomach upset. These were mostly mild to moderate and lined up with what is already known about injectable GLP-1 drugs. The biggest limits are the ones the authors call out directly. There was no group that simply continued tirzepatide or semaglutide, so we cannot say if the pill is just as good as the shot. And one year is not long enough to know what happens over five or ten years of real-life use.
Practical takeaways
- If you are taking tirzepatide or semaglutide and worried about weight regain when you stop, talk to your doctor about whether an oral GLP-1 pill might be an option once it becomes available.
- Expect some weight regain after stopping any GLP-1 therapy without a maintenance plan, since the placebo group still kept about a third to half of their weight loss on their own.
- Prepare for mild stomach side effects in the first weeks of switching to an oral GLP-1, and tell your doctor if nausea or diarrhea becomes hard to manage.
- Keep the lifestyle habits you built during weight loss, since medication works best alongside steady eating patterns, sleep, and movement.
Related Studies and Research
- A lower tirzepatide dose can help keep weight off long-term
- Long-term oxygen treatment trial LOTT and health benefits
- Single-dose psilocybin vs placebo: first double-blind depression trial
- Oral maintenance therapy for cholera in adults (1968 Lancet)
FAQs
Is orforglipron available now or do I need to wait?
Orforglipron is still investigational and has not been approved for sale at the time of this trial. The ATTAIN-MAINTAIN study is part of the broader ATTAIN phase 3 program that regulators will use to decide whether to approve it. If the agency reviews go well, an approved version could become available in the next year or two, though timing depends on the manufacturer and each country’s regulator. For now, talk to your doctor about which approved options fit your situation best.
Why is a pill version of a GLP-1 such a big deal?
A daily pill removes several real-world problems that keep people from staying on weight-loss medication. There are no needles, no need to store the drug cold, and far fewer issues when traveling or living in places without reliable refrigeration. Pills are also generally cheaper to make and ship at scale, which matters globally since obesity affects more than a billion people. Together, those factors could let many more people stay on therapy long enough to actually keep weight off.
Should I expect to keep all of my weight loss if I switch to orforglipron?
Probably not all of it, but most of it. In this trial, people who switched from the shot to the pill kept about three-quarters or more of the weight they had lost. That is a strong result, but it still means a small amount of regain is normal. The trial did not test switching from the shot to the pill against simply staying on the shot, so it is still unclear whether the pill is fully equivalent for everyone.
Bottom Line
This trial is the first to show that a daily oral GLP-1 pill can hold onto most of the weight loss achieved with injectable tirzepatide or semaglutide over a full year. People who switched to orforglipron kept about 75 to 80% of their earlier weight loss, while those on placebo lost much more ground. The cardiometabolic benefits, including better blood pressure, lipids, and waist size, were also preserved. If approved, orforglipron could become a more convenient and globally scalable way to make weight loss last.
